ROIV insider transaction filings
Roivant Sciences Ltd. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-21. Screen ROIV transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-21 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 172,899 @ $3.85 · Sale (S): 172,899 @ $37.17 · Option exercise (M): 17,519 @ $3.85 · Sale (S): 17,519 @ $37.30 · Option exercise (M): 144,756 @ $3.85 · Sale (S): 144,756 @ $36.48 · +3 more | EDGAR |
| 2026-08-18 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 243,177 @ $3.85 · Sale (S): 243,177 @ $36.23 · Option exercise (M): 284,707 @ $3.85 · Sale (S): 284,707 @ $36.25 · Option exercise (M): 105,141 @ $3.85 · Sale (S): 105,141 @ $36.59 · +5 more | EDGAR |
| 2026-07-29 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $34.95 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4 | Epperly Melissa B, — Director | Grant/award (A): 543 @ $0 | EDGAR |
| 2026-07-21 | 4 | Oren Ilan — Director | Grant/award (A): 775 @ $0 | EDGAR |
| 2026-07-21 | 4 | MOMTAZEE JAMES C — Director | Grant/award (A): 405 @ $0 | EDGAR |
| 2026-07-02 | 4 | Gline Matthew — CEO, Director | Tax withholding (F): 76,171 @ $35.39 | EDGAR |
| 2026-07-02 | 4 | Torti Frank — President and Vant Chair | Tax withholding (F): 40,310 @ $35.39 | EDGAR |
| 2026-07-02 | 4 | Sukhatme Mayukh — President & CIO, Director | Tax withholding (F): 46,878 @ $35.39 | EDGAR |
| 2026-07-02 | 4 | Fitzgerald Meghan — Director | Option exercise (M): 10,000 @ $8.80 · Sale (S): 10,000 @ $34.90 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Epperly Melissa B, — Director | Option exercise (M): 17,750 @ $4.46 · Sale (S): 15,002 @ $34.32 · Sale (S): 2,748 @ $34.71 · Option exercise (M): 17,750 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Gold Daniel Allen — Director | Sale (S): 300,783 @ $33.92 · Sale (S): 325,000 @ $34.07 · Sale (S): 200,000 @ $34.44 · Sale (S): 600,000 @ $34.59 · Sale (S): 12,380 @ $35.28 | EDGAR |
| 2026-06-30 | 4 | QVT Financial LP | Sale (S): 300,783 @ $33.92 · Sale (S): 325,000 @ $34.07 · Sale (S): 200,000 @ $34.44 · Sale (S): 600,000 @ $34.59 · Sale (S): 12,380 @ $35.28 | EDGAR |
| 2026-06-30 | 4 | MANCHESTER KEITH S — Director | Sale (S): 300,783 @ $33.92 · Sale (S): 325,000 @ $34.07 · Sale (S): 200,000 @ $34.44 · Sale (S): 600,000 @ $34.59 · Sale (S): 12,380 @ $35.28 · Sale (S): 200,000 @ $35.45 | EDGAR |
| 2026-06-29 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 500,000 @ $3.85 · Sale (S): 500,000 @ $34.13 · Option exercise (M): 500,000 @ $3.85 · Sale (S): 500,000 @ $34.08 · Option exercise (M): 500,000 (derivative) @ $0 · Option exercise (M): 500,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 153,766 @ $33.05 · Sale (S): 46,234 @ $33.51 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Pulik Richard — CFO | Tax withholding (F): 2,129 @ $31.43 | EDGAR |
| 2026-06-23 | 4 | Humes Jennifer — Chief Accounting Officer | Tax withholding (F): 3,582 @ $31.43 | EDGAR |
| 2026-05-22 | 4 | Venker Eric — President & Immunovant CEO | Tax withholding (F): 34,483 @ $32.41 · Option exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $30.27 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Pulik Richard — CFO | Tax withholding (F): 18,962 @ $32.41 | EDGAR |
| 2026-04-22 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $29.59 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Pulik Richard — CFO | Grant/award (A): 60,644 @ $0 · Grant/award (A): 84,026 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Humes Jennifer — Chief Accounting Officer | Grant/award (A): 29,173 @ $0 · Grant/award (A): 27,157 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Epperly Melissa B, — Director | Grant/award (A): 670 @ $0 | EDGAR |
| 2026-04-21 | 4 | Oren Ilan — Director | Grant/award (A): 896 @ $0 · Tax withholding (F): 95 @ $29.83 | EDGAR |
| 2026-04-21 | 4 | MOMTAZEE JAMES C — Director | Grant/award (A): 469 @ $0 · Tax withholding (F): 94 @ $29.83 | EDGAR |
| 2026-04-20 | 4 | Gline Matthew — CEO, Director | Sale (S): 289,774 @ $29.16 | EDGAR |
| 2026-04-10 | 4 | Humes Jennifer — Chief Accounting Officer | Sale (S): 13,538 @ $28.37 | EDGAR |
| 2026-04-02 | 4 | Torti Frank — President and Vant Chair | Tax withholding (F): 160,035 @ $27.70 | EDGAR |
| 2026-04-01 | 4 | Gline Matthew — CEO, Director | Option exercise (M): 97,319 · Tax withholding (F): 53,826 @ $26.41 · Tax withholding (F): 304,684 @ $27.70 · Option exercise (M): 2,178,150 (derivative) @ $11.50 | EDGAR |
| 2026-04-01 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 58,391 · Tax withholding (F): 29,809 @ $26.41 · Tax withholding (F): 187,512 @ $27.70 · Option exercise (M): 1,306,889 (derivative) @ $11.50 | EDGAR |
| 2026-03-30 | 4 | Fitzgerald Meghan — Director | Option exercise (M): 70,000 @ $8.80 · Sale (S): 70,000 @ $27.45 · Option exercise (M): 70,000 (derivative) @ $0 | EDGAR |
| 2026-03-24 | 4 | Pulik Richard — CFO | Tax withholding (F): 1,546 @ $27.70 | EDGAR |
| 2026-03-24 | 4 | Humes Jennifer — Chief Accounting Officer | Tax withholding (F): 14,526 @ $27.70 | EDGAR |
| 2026-03-19 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $28.24 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Epperly Melissa B, — Director | Sale (S): 41,861 @ $28.68 | EDGAR |
| 2026-02-24 | 4 | Pulik Richard — CFO | Tax withholding (F): 1,000 @ $27.15 | EDGAR |
| 2026-02-24 | 4 | Venker Eric — President & Immunovant CEO | Tax withholding (F): 7,051 @ $27.15 | EDGAR |
| 2026-02-23 | 4 | Torti Frank — President and Vant Chair | Option exercise (M): 1,400,000 @ $3.85 · Sale (S): 1,400,000 @ $27.42 · Option exercise (M): 1,012,610 @ $3.85 · Sale (S): 1,012,610 @ $27.15 · Option exercise (M): 587,390 @ $3.85 · Sale (S): 587,390 @ $27.51 · +3 more | EDGAR |
| 2026-02-18 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $26.49 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Gold Daniel Allen — Director | Sale (S): 425,000 @ $26.67 · Sale (S): 150,000 @ $26.72 · Sale (S): 275,000 @ $26.76 · Sale (S): 150,784 @ $26.49 · Sale (S): 225,000 @ $26.50 | EDGAR |
| 2026-02-13 | 4 | QVT Financial LP | Sale (S): 425,000 @ $26.67 · Sale (S): 150,000 @ $26.72 · Sale (S): 275,000 @ $26.76 · Sale (S): 150,784 @ $26.49 · Sale (S): 225,000 @ $26.50 | EDGAR |
| 2026-02-13 | 4 | MANCHESTER KEITH S — Director | Sale (S): 425,000 @ $26.67 · Sale (S): 150,000 @ $26.72 · Sale (S): 275,000 @ $26.76 · Sale (S): 150,784 @ $26.49 · Sale (S): 225,000 @ $26.50 | EDGAR |
| 2026-02-11 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 651,558 @ $12.68 · Sale (S): 339,441 @ $26.47 · Other (J): 312,117 @ $26.47 · Option exercise (M): 651,558 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Oren Ilan — Director | Grant/award (A): 1,164 @ $0 · Tax withholding (F): 124 @ $22.98 | EDGAR |
| 2026-01-22 | 4 | Epperly Melissa B, — Director | Grant/award (A): 815 @ $0 · Tax withholding (F): 54 @ $22.98 | EDGAR |
| 2026-01-22 | 4 | MOMTAZEE JAMES C — Director | Grant/award (A): 609 @ $0 · Tax withholding (F): 122 @ $22.98 | EDGAR |
| 2026-01-14 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $21.92 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2025-12-31 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 748,358 @ $12.68 · Sale (S): 311,873 @ $21.74 · Other (J): 436,485 @ $21.74 · Option exercise (M): 2,449,877 @ $12.68 · Sale (S): 1,018,995 @ $21.71 · Other (J): 1,430,882 @ $21.71 · +2 more | EDGAR |
| 2025-12-29 | 4 | Torti Frank — President and Vant Chair | Grant/award (A): 175,380 @ $22.45 · Other (J): 64,891 @ $22.47 · Gift (G): 110,489 @ $0 | EDGAR |
Recent 8-K events — Roivant Sciences Ltd.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-20 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-17 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ROIV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →